CardieX Limited Logo

CardieX Limited

CDX.AX

(1.2)
Stock Price

0,07 AUD

-151.47% ROA

-3106.65% ROE

-0.61x PER

Market Cap.

16.179.625,00 AUD

105.7% DER

0% Yield

-90.59% NPM

CardieX Limited Stock Analysis

CardieX Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

CardieX Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (31%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.09x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Assets Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 ROE

Negative ROE (-136.32%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-82.09%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

CardieX Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

CardieX Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

CardieX Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

CardieX Limited Revenue
Year Revenue Growth
2005 3.106.000
2006 3.334.000 6.84%
2007 4.874.000 31.6%
2008 6.450.599 24.44%
2009 11.209.113 42.45%
2010 9.198.496 -21.86%
2011 7.458.450 -23.33%
2012 6.441.493 -15.79%
2013 9.055.721 28.87%
2014 5.053.284 -79.2%
2015 5.467.457 7.58%
2016 5.019.387 -8.93%
2017 4.327.283 -15.99%
2018 4.006.091 -8.02%
2019 3.907.093 -2.53%
2020 4.292.552 8.98%
2020 4.292.552 0%
2021 5.001.134 14.17%
2022 4.066.982 -22.97%
2023 4.604.284 11.67%
2024 5.738.160 19.76%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

CardieX Limited Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 2.154.111 100%
2009 2.265.600 4.92%
2010 1.963.756 -15.37%
2011 2.255.351 12.93%
2012 2.113.466 -6.71%
2013 1.443.118 -46.45%
2014 1.384.992 -4.2%
2015 1.623.980 14.72%
2016 1.593.312 -1.92%
2017 1.475.724 -7.97%
2018 1.543.420 4.39%
2019 1.476.796 -4.51%
2020 626.056 -135.89%
2020 626.056 0%
2021 918.112 31.81%
2022 2.376.723 61.37%
2023 3.908.272 39.19%
2024 6.219.024 37.16%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

CardieX Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 1.373.000
2006 1.787.000 23.17%
2007 2.530.000 29.37%
2008 2.421.695 -4.47%
2009 3.352.176 27.76%
2010 2.182.473 -53.6%
2011 1.741.697 -25.31%
2012 1.891.740 7.93%
2013 2.162.432 12.52%
2014 2.081.688 -3.88%
2015 2.153.614 3.34%
2016 2.720.007 20.82%
2017 2.201.754 -23.54%
2018 1.994.678 -10.38%
2019 3.296.102 39.48%
2020 6.619.178 50.2%
2020 6.619.178 0%
2021 8.421.206 21.4%
2022 11.849.519 28.93%
2023 14.966.621 20.83%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

CardieX Limited EBITDA
Year EBITDA Growth
2005 -2.982.000
2006 -5.190.000 42.54%
2007 -6.275.000 17.29%
2008 -4.334.299 -44.78%
2009 -2.698.657 -60.61%
2010 -1.665.990 -61.99%
2011 -2.520.468 33.9%
2012 -2.661.018 5.28%
2013 1.009.946 363.48%
2014 -3.102.298 132.55%
2015 -2.897.438 -7.07%
2016 -5.383.335 46.18%
2017 -4.441.087 -21.22%
2018 -2.937.209 -51.2%
2019 -2.707.524 -8.48%
2020 -3.155.687 14.2%
2020 -2.950.445 -6.96%
2021 -5.094.784 42.09%
2022 -10.936.638 53.42%
2023 -18.712.784 41.56%
2024 -31.788.920 41.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

CardieX Limited Gross Profit
Year Gross Profit Growth
2005 2.234.000
2006 2.369.000 5.7%
2007 3.863.000 38.67%
2008 5.164.529 25.2%
2009 9.469.300 45.46%
2010 8.288.714 -14.24%
2011 6.387.691 -29.76%
2012 5.449.874 -17.21%
2013 7.843.858 30.52%
2014 4.110.397 -90.83%
2015 4.560.277 9.87%
2016 3.945.086 -15.59%
2017 3.310.610 -19.16%
2018 3.124.321 -5.96%
2019 3.102.692 -0.7%
2020 3.594.376 13.68%
2020 3.594.376 0%
2021 4.095.852 12.24%
2022 3.125.574 -31.04%
2023 3.698.435 15.49%
2024 -16.703.232 122.14%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

CardieX Limited Net Profit
Year Net Profit Growth
2005 -2.696.000
2006 -4.005.000 32.68%
2007 -5.183.000 22.73%
2008 -3.792.731 -36.66%
2009 -1.691.433 -124.23%
2010 -1.220.057 -38.64%
2011 -3.081.084 60.4%
2012 -1.985.519 -55.18%
2013 2.734.023 172.62%
2014 -2.663.508 202.65%
2015 -1.440.177 -84.94%
2016 -4.805.892 70.03%
2017 -4.363.571 -10.14%
2018 -2.961.225 -47.36%
2019 -2.979.278 0.61%
2020 -3.320.427 10.27%
2020 -3.320.427 0%
2021 -5.545.597 40.12%
2022 -11.383.382 51.28%
2023 -19.063.305 40.29%
2024 -33.781.604 43.57%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

CardieX Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 0
2006 0 0%
2007 -1 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

CardieX Limited Free Cashflow
Year Free Cashflow Growth
2005 -2.516.000
2006 -4.591.000 45.2%
2007 -4.753.000 3.41%
2008 -3.946.672 -20.43%
2009 -769.901 -412.62%
2010 -2.639.593 70.83%
2011 -1.976.846 -33.53%
2012 -1.574.611 -25.55%
2013 1.718.611 191.62%
2014 -1.408.357 222.03%
2015 -2.012.758 30.03%
2016 -4.995.548 59.71%
2017 -3.082.875 -62.04%
2018 -212.410 -1351.38%
2019 -2.446.759 91.32%
2020 -1.907.747 -28.25%
2021 -4.331.133 55.95%
2022 -10.055.432 56.93%
2023 -12.076.626 16.74%
2024 -9.246.503 -30.61%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

CardieX Limited Operating Cashflow
Year Operating Cashflow Growth
2005 -2.454.000
2006 -4.267.000 42.49%
2007 -4.488.000 4.92%
2008 -3.778.473 -18.78%
2009 -637.556 -492.65%
2010 -2.578.551 75.27%
2011 -1.895.004 -36.07%
2012 -1.182.322 -60.28%
2013 1.776.662 166.55%
2014 -1.363.948 230.26%
2015 -1.965.647 30.61%
2016 -4.920.151 60.05%
2017 -3.065.630 -60.49%
2018 -207.494 -1377.45%
2019 -2.290.773 90.94%
2020 -1.698.851 -34.84%
2021 -3.972.794 57.24%
2022 -9.617.376 58.69%
2023 -11.996.350 19.83%
2024 -9.135.795 -31.31%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

CardieX Limited Capital Expenditure
Year Capital Expenditure Growth
2005 62.000
2006 324.000 80.86%
2007 265.000 -22.26%
2008 168.199 -57.55%
2009 132.345 -27.09%
2010 61.042 -116.81%
2011 81.842 25.41%
2012 392.289 79.14%
2013 58.051 -575.77%
2014 44.409 -30.72%
2015 47.111 5.74%
2016 75.397 37.52%
2017 17.245 -337.21%
2018 4.916 -250.79%
2019 155.986 96.85%
2020 208.896 25.33%
2021 358.339 41.7%
2022 438.056 18.2%
2023 80.276 -445.69%
2024 110.708 27.49%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

CardieX Limited Equity
Year Equity Growth
2005 18.795.000
2006 14.406.000 -30.47%
2007 9.382.000 -53.55%
2008 5.961.497 -57.38%
2009 4.645.022 -28.34%
2010 3.736.765 -24.31%
2011 3.032.122 -23.24%
2012 1.884.420 -60.9%
2013 4.878.933 61.38%
2014 3.283.947 -48.57%
2015 4.333.993 24.23%
2016 3.140.775 -37.99%
2017 1.328.486 -136.42%
2018 4.596.213 71.1%
2019 6.950.935 33.88%
2020 5.880.001 -18.21%
2021 7.910.349 25.67%
2022 6.611.313 -19.65%
2023 -1.000.771 760.62%
2024 3.204.081 131.23%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

CardieX Limited Assets
Year Assets Growth
2005 20.336.000
2006 15.845.000 -28.34%
2007 11.404.000 -38.94%
2008 7.950.918 -43.43%
2009 7.900.161 -0.64%
2010 5.901.303 -33.87%
2011 5.251.336 -12.38%
2012 4.181.758 -25.58%
2013 6.375.007 34.4%
2014 4.631.270 -37.65%
2015 5.953.596 22.21%
2016 4.603.536 -29.33%
2017 2.960.093 -55.52%
2018 6.413.907 53.85%
2019 13.211.974 51.45%
2020 10.675.276 -23.76%
2021 11.264.180 5.23%
2022 12.377.864 9%
2023 14.302.372 13.46%
2024 11.519.945 -24.15%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

CardieX Limited Liabilities
Year Liabilities Growth
2005 1.541.000
2006 1.439.000 -7.09%
2007 2.022.000 28.83%
2008 1.989.421 -1.64%
2009 3.255.139 38.88%
2010 2.164.538 -50.38%
2011 2.219.214 2.46%
2012 2.297.338 3.4%
2013 1.496.074 -53.56%
2014 1.347.323 -11.04%
2015 1.619.603 16.81%
2016 1.462.761 -10.72%
2017 1.631.607 10.35%
2018 1.817.694 10.24%
2019 6.261.039 70.97%
2020 4.795.275 -30.57%
2021 3.353.831 -42.98%
2022 5.766.551 41.84%
2023 15.303.143 62.32%
2024 8.315.863 -84.02%

CardieX Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.1
Net Income per Share
-0.09
Price to Earning Ratio
-0.61x
Price To Sales Ratio
0.84x
POCF Ratio
-0.77
PFCF Ratio
-1.16
Price to Book Ratio
3.32
EV to Sales
1.02
EV Over EBITDA
-2.06
EV to Operating CashFlow
-1.42
EV to FreeCashFlow
-1.4
Earnings Yield
-1.64
FreeCashFlow Yield
-0.86
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.18
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.09
Income Quality
0.79
ROE
-31.07
Return On Assets
-1.51
Return On Capital Employed
-3.49
Net Income per EBT
0.98
EBT Per Ebit
1.39
Ebit per Revenue
-0.67
Effective Tax Rate
-0.16

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.24
Stock Based Compensation to Revenue
0.05
Gross Profit Margin
0.07
Operating Profit Margin
-0.67
Pretax Profit Margin
-0.93
Net Profit Margin
-0.91

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.07
Free CashFlow per Share
-0.07
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.01
Capex to Depreciation
1.38
Return on Invested Capital
-2.27
Return on Tangible Assets
-1.51
Days Sales Outstanding
6.65
Days Payables Outstanding
67.17
Days of Inventory on Hand
51.93
Receivables Turnover
54.88
Payables Turnover
5.43
Inventory Turnover
7.03
Capex per Share
0

Balance Sheet

Cash per Share
0,03
Book Value per Share
0,02
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.02
Interest Debt per Share
0.02
Debt to Equity
1.06
Debt to Assets
0.29
Net Debt to EBITDA
-0.36
Current Ratio
1.18
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
2656282
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
2524693.5
Debt to Market Cap
0.21

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

CardieX Limited Dividends
Year Dividends Growth

CardieX Limited Profile

About CardieX Limited

CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company undertakes contracts with pharmaceutical companies for the use of SphygmoCor XCEL devices; provides lab and data management services for clinical trials comprising end-to-end service that delivers clean datasets to study sponsors. It also develops home vascular health solutions, remote patient monitoring, decentralized clinical trials and solutions wearables, and medical health apps under the CONNEQT name, as well as CONNEQT Pulse device, a home-based heart health vital signs monitoring system, that measures central blood pressure, arterial waveforms, and various other proprietary arterial health parameters through its SphygmoCor technology. The company serves hospitals, clinics, research institutions and pharmaceutical companies. It has strategic collaboration agreement with LifeQ, Inc for wearable devices. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is based in Sydney, Australia.

CEO
Mr. Craig R. Cooper BEC, L.L.B
Employee
26
Address
55 Lime Street
Sydney, 2000

CardieX Limited Executives & BODs

CardieX Limited Executives & BODs
# Name Age
1 Dr. Sanjeev Bhavnani
Chief Clinical Officer
70
2 Mr. Douglas T. Kurschinski
Executive Vice President & Head of Global Sales for AtCor Medical Division
70
3 Ms. Louisa Ho
Company Secretary
70
4 Mr. Niall Charles Edgar Cairns ACA, B.Ec, FAICD
Co-Founder & Executive Chairman
70
5 Mr. Craig R. Cooper BEC, L.L.B.
Co-Founder, Group Chief Executive Officer, MD & Executive Director
70
6 Dr. Ahmad Qasem Ph.D.
Chief Science & Research Officer
70
7 Dr. Steven Kesten
Chief Medical Officer
70
8 Dr. Mark Gorelick Ph.D.
Chief Product Officer
70
9 Ms. Catherine Liao
Chief Strategy Officer
70

CardieX Limited Competitors